Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral - Gynaecological cancers 2

LBA36 - Safety and antitumor activity of dostarlimab in patients (pts) with advanced or recurrent DNA mismatch repair deficient (dMMR) or proficient (MMRp) endometrial cancer (EC): Results from GARNET


18 Sep 2020


Mini Oral - Gynaecological cancers 2



Tumour Site

Endometrial Cancer


Ana Oaknin


Annals of Oncology (2020) 31 (suppl_4): S1142-S1215. 10.1016/annonc/annonc325


A. Oaknin1, L. Gilbert2, A.V. Tinker3, R. Sabatier4, V. Boni5, D.M. O'Malley6, S. Ghamande7, L. Duska8, P. Ghatage9, W. Guo10, E. Im11, B. Pothuri12

Author affiliations

  • 1 Medical Oncology Department, Vall d´Hebron University Hospital, Vall d´Hebron Institute of Oncology (VHIO), 08035 - Barcelona/ES
  • 2 Department Of Obstetrics And Gynecology, McGill University Health Centre-RI, Montreal/CA
  • 3 Medical Oncology Department, BC Cancer, Vancouver/CA
  • 4 Department Of Medical Oncology, Institut Paoli Calmettes, Aix-Marseille University, Marseille/FR
  • 5 Department Of Oncology, Centro Integral Oncológico Clara Campal, Hospital Universitario HM Sanchinarro, Madrid/ES
  • 6 Department Of Obstetrics And Gynecology, The Ohio State University – James CCC, Columbus/US
  • 7 Department Of Obstetrics And Gynecology, Georgia Cancer Center, Augusta University, Augusta/US
  • 8 Obstetrics And Gynecology, Emily Couric Clinical Cancer Center, University of Virginia, Charlottesville/US
  • 9 Department Of Gynecological Oncology, University of Calgary, Calgary/CA
  • 10 Clinical Science, GlaxoSmithKline, Waltham/US
  • 11 Clinical Science, GlaxoSmithKline, 02451 - Waltham/US
  • 12 Department Of Obstetrics And Gynecology, Division of Gynecologic Oncology, Perlmutter Cancer Center, New York University, New York/US


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract LBA36


Dostarlimab (TSR-042) is a humanized programmed death (PD)-1 receptor monoclonal antibody that blocks interaction with the PD-1 ligands. GARNET is a phase I study assessing antitumor activity and safety of dostarlimab monotherapy in pts with solid tumors.


This multicenter, open-label, single-arm study includes dose escalation and expansion parts. Here we report on 2 independent expansion cohorts of pts with recurrent or advanced EC (dMMR EC and MMRp EC, determined by immunohistochemistry [IHC]) that progressed on or after a platinum-based chemotherapy regimen. Pts received 500 mg dostarlimab IV Q3W for 4 cycles, then 1000 mg Q6W until disease progression, discontinuation, or withdrawal. The primary endpoints are objective response rate (ORR) and duration of response (DOR) by blinded independent central review using RECIST v1.1.


In total, 126 dMMR and 145 MMRp pts identified by IHC were enrolled and dosed. Of these, 103 and 142 pts had sufficient follow-up time (24 wks) for efficacy analyses, respectively. dMMR ORR was 44.7%; MMRp ORR was 13.4% (Table). Median DOR and OS were not reached. The most common grade ≥3 TEAEs (N=271) were anemia (12.2%), abdominal pain (4.8%), and dyspnea (4.1%). The most common grade ≥3 immune-related TEAEs were diarrhea, aspartate aminotransferase increased, and alanine aminotransferase increased (1.8% each). There were no treatment-related deaths.


Dostarlimab demonstrated durable antitumor activity in both dMMR and MMRp advanced/recurrent EC. dMMR status by IHC was associated with a higher response rate. No new safety signals were detected. These cohorts are the largest prospective evaluation of a PD-(L)1 therapy in EC to date. Table: LBA36

Variable, unit dMMR N=103 MMRp N=142
Median follow-up, mo 16.3 11.5
ORR, n (% [95% CI]) Complete response, n (%) Partial response, n (%) Stable disease, n (%) 46 (44.7 [34.9–54.8]) 11 (10.7) 35 (34.0) 13 (12.6) 19 (13.4 [8.3–20.1]) 3 (2.1) 16 (11.3) 31 (21.8)
Disease control rate, n (% [95% CI]) 59 (57.3 [47.2–67.0]) 50 (35.2 [27.4–43.7])
Response ongoing, n (%) 41 (89.1) 12 (63.2)
18 mo DOR, % (95% CI) 79.2 (54.9–91.3) 61.3 (32.5–80.8)

Clinical trial identification


Editorial acknowledgement

Writing and editorial support, funded by GlaxoSmithKline (Waltham, MA, USA) and coordinated by Heather Ostendorff-Back, PhD of GlaxoSmithKline was provided by Nicole Renner, PhD and Anne Cooper of Ashfield Healthcare Communications (Middletown, CT, USA).

Legal entity responsible for the study

GlaxoSmithKline, Waltham, MA, USA.


GlaxoSmithKline, Waltham, MA, USA.


A. Oaknin: Honoraria (institution), Advisory/Consultancy: AstraZeneca; Honoraria (institution), Advisory/Consultancy: Tesaro; Honoraria (institution), Advisory/Consultancy: Clovis; Honoraria (institution), Advisory/Consultancy: PharmaMar; Honoraria (institution), Advisory/Consultancy: Roche. L. Gilbert: Advisory/Consultancy: Merck; Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: Pfizer. A.V. Tinker: Advisory/Consultancy, Research grant/Funding (institution): AstraZeneca. R. Sabatier: Research grant/Funding (institution): Eisai; Advisory/Consultancy, Non-remunerated activity/ies: Roche; Advisory/Consultancy, Non-remunerated activity/ies: Pfizer; Advisory/Consultancy: Tesaro; Advisory/Consultancy: Novartis; Advisory/Consultancy, Non-remunerated activity/ies: AstraZeneca; Non-remunerated activity/ies: Amgen. D.M. O'Malley: Advisory/Consultancy: Tesaro, Immunogen, Eisai, Agenus, GSK; Advisory/Consultancy: Clovis, Ambry, AbbVie; Advisory/Consultancy: Janssen/J&J, Regeneron, Novacure, Myraid Genetics, Tarveda; Advisory/Consultancy: Amgen; Advisory/Consultancy: Genentech/Roche, Merck; Research grant/Funding (institution): VentiRx, Array Biopharma, EMD Serono, Ergomed; Research grant/Funding (institution): Ajinomoto Inc, Ludwig Cancer Research; Research grant/Funding (institution): Stemcentrx, Inc, Cerulean Pharma, GOG Foundation; Research grant/Funding (institution): BMS, Serono Inc, Tracon Pharmaceuticals; Research grant/Funding (institution): Yale University, New Mexico Cancer Care Alliance; Research grant/Funding (institution): INC Research, Inc., Inventiv Health Clinical; Research grant/Funding (institution): Iovance Biotherapeutics, Inc, PRA Intl. S. Ghamande: Advisory/Consultancy, Research grant/Funding (institution): Seattle Genetics; Speaker Bureau/Expert testimony, Research grant/Funding (institution): Tesaro; Speaker Bureau/Expert testimony, Research grant/Funding (institution): GlaxoSmithKline; Research grant/Funding (institution): Merck; Research grant/Funding (institution): Roche; Research grant/Funding (institution): Genentech; Research grant/Funding (institution): Takeda; Research grant/Funding (institution): Advaxis; Research grant/Funding (institution): BMS; Research grant/Funding (institution): Clovis; Research grant/Funding (institution): AbbVie. L. Duska: Research grant/Funding (institution): Merck, Genentech/Roche, GlaxoSmithKline, Inovio; Advisory/Consultancy: AstraZeneca, Genentech/Roche, MorphoTek; Advisory/Consultancy: Merck, Cue Biopharma; Licensing/Royalties: Elsevier, JB Learning. W. Guo: Full/Part-time employment: GlaxoSmithKline. E. Im: Full/Part-time employment: GlaxoSmithKline. B. Pothuri: Advisory/Consultancy, Research grant/Funding (institution), Non-remunerated activity/ies: Tesaro; Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: Clovis Oncology. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.